All In Biotech

Drug Trial Radar · NCT05709444

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease to Assess the Efficacy in Reducing Urinary Protein and Maintaining Podocyte Density and Function

Last checked: Nov 19, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Dec 26, 2022

Primary completion

Apr 26, 2024

Study completion Apr 26, 2024

Sponsor

Lead sponsor
Palatin Technologies, IncIndustry
Sponsor type
Industry
First posted
Feb 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects will remain in trial for further assessment and undergo a diagnostic renal biopsy to assess the effect of melanocortin therapy on diabetic histopathology at 12 months.

Conditions

  • Kidney Disease

Interventions

  • BremelanotideDrug

    Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).

  • RAAS inhibition therapyDrug

    RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate the efficacy of 0.5 mg subcutaneous BMT (given twice a day), used in combination with a subject's maximum tolerated dose of RAAS inhibition therapy, reduces urinary protein by 50% from baseline UP/Cr levels.Time frame: Baseline to after six months of combined therapy (RAAS inhibition therapy plus BMT).
  2. To determine the incidence of overall adverse events, related adverse events, a composite of adverse events of special interest, serious adverse events, and the incidence of BMT discontinuation.Time frame: Baseline to after six months of combined therapy (RAAS inhibition therapy plus BMT).

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • California Institute of Renal Research

    Chula Vista, California

  • California Institute of Renal Research DBA - Balboa Research

    La Mesa, California

  • Georgia Nephrology, LLC DBA -GA Nephrology Research Institute

    Decatur, Georgia

  • Georgia Nephrology, LLC [DBA] GA Nephrology Research Institute

    Lawrenceville, Georgia

  • Brookview Hills Research Associates, LLC

    Winston-Salem, North Carolina

  • Northeast Research Center, LLC

    Bethlehem, Pennsylvania

  • Nephrotex Research Group

    Dallas, Texas

  • Prolator Clinical Research Center

    Houston, Texas

  • Clinical Advancement Center, PLLC

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.